Nucleotech Medical Systems International Profile
Key Indicators
- Authorised Capital ₹ 2.50 Cr
as on 19-12-2024
- Paid Up Capital ₹ 2.50 Cr
as on 19-12-2024
- Company Age 18 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 2.40 Cr
as on 19-12-2024
- Revenue -14.94%
(FY 2022)
- Profit 70.80%
(FY 2022)
- Ebitda -38.33%
(FY 2022)
- Net Worth -0.16%
(FY 2022)
- Total Assets -11.14%
(FY 2022)
About Nucleotech Medical Systems International
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 Cr and a paid-up capital of Rs 2.50 Cr.
The company has closed loans amounting to ₹2.40 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Suman Saxena, Amaltash Saxena, and Arun Saxena serve as directors at the Company.
- CIN/LLPIN
U33100MH2006PLC161113
- Company No.
161113
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
13 Apr 2006
- Date of AGM
29 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Raigarh, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Nucleotech Medical Systems International Ltd offer?
Nucleotech Medical Systems International Ltd offers a wide range of products and services, including Metal, Security & Safety Detectors, Security Metal Baggage & Vehicle Scanner, Diagnostic Medical Imaging Equipment, X Ray Machine, Fuji X Ray Machine, X Ray Machine Parts.
Who are the key members and board of directors at Nucleotech Medical Systems International?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Arun Saxena  | Director | 05-Sep-2009 | Current |
| Suman Saxena | Director | 29-Aug-2014 | Current |
| Amaltash Saxena | Director | 30-Sep-2016 | Current |
Financial Performance of Nucleotech Medical Systems International.
Nucleotech Medical Systems International Ltd, for the financial year ended 2022, experienced significant reduction in revenue, with a 14.94% decrease. The company also saw a substantial improvement in profitability, with a 70.8% increase in profit. The company's net worth dipped by a decrease of 0.16%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nucleotech Medical Systems International?
In 2019, Nucleotech Medical Systems International had a promoter holding of 93.94% and a public holding of 6.06%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Teknochem Graphite Equipments (India) Private LimitedActive 30 years 6 monthsAmaltash Saxena is a mutual person
- Blast Carboblocks Private LimitedActive 42 years 8 months
Amaltash Saxena and Arun Saxena are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bank Of Baroda Creation Date: 22 Nov 2007 | ₹1.20 Cr | Satisfied |
Bank Of Baroda Creation Date: 22 Nov 2007 | ₹1.20 Cr | Satisfied |
How Many Employees Work at Nucleotech Medical Systems International?
Unlock and access historical data on people associated with Nucleotech Medical Systems International, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nucleotech Medical Systems International, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nucleotech Medical Systems International's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
